Industry landscapes
The companies, capital and talent shaping life sciences in Seattle. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
No company example met every recorded classification, independence and public-profile gate in this snapshot. The live directory may have newer qualifying companies.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
20 of 257 tracked companies have open roles.
166 of 257 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 564 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 18.3% of disclosed capital, while 35.4% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $268.22M | 17 | 33 |
| 2017 | $511.09M | 19 | 45 |
| 2018 | $460.53M | 12 | 38 |
| 2019 | $440.84M | 9 | 36 |
| 2020 | $1.93B | 15 | 49 |
| 2021 | $1.87B | 13 | 47 |
| 2022 | $878.17M | 7 | 36 |
| 2023 | $815.46M | 8 | 34 |
| 2024 | $317.31M | 4 | 24 |
| 2025 | $919.43M | 1 | 28 |
Share of all disclosed company funding.
605 recorded rounds since 2016
Recorded participation in life sciences company rounds since 2016.
Backed by Frazier Life Sciences and TPG and others.
Backed by .
Backed by Chalfen Ventures and Osage Venture Partners and others.
Backed by F-Prime Capital and Arch Venture Partners and others.
Participating investors were not recorded in this snapshot.
Backed by Regeneron Pharmaceuticals and Trinity Health and others.
Backed by SoftBank Vision Fund and Temasek and others.
Backed by Rock Springs Capital and Viking Global Investors and others.
Backed by Perceptive Advisors and Xontogeny and others.
Backed by Frazier Life Sciences and Jeito and others.
Backed by New Enterprise Associates and Yosemite and others.
Backed by RA Capital Management and Qatar Investment Authority and others.
Backed by Deerfield and Petrichor and others.
Annual accounts for reporting companies linked to this landscape, on like-for-like currency and reporting bases.
Display conversions use the dated reference rates above. Where a verified rate is unavailable, figures retain their source currency. Each reporting cohort keeps its currency and accounting basis separate.
FY2025 · company accounts; aggregate reporting threshold not met · 2 reporting entities from 15 eligible matches.
Sum of reporting-entity revenue; not Seattle market sales.
Combined result for the same cohort.
Combined net income ÷ combined revenue.
The middle covered reporting entity.
None of 2 covered entities.
Share of covered revenue from the five largest entities.
Reported cohort totals by year; coverage is stated for every period.
Bar height shows revenue. Changes in coverage can affect totals.
FY2025 · 2 reporting entities
Up to eight fixed company previews show financial amounts. Search and sort the wider company list, then continue in Radar.
| Company / reporting entity | Revenue | Net profit / loss | Net margin | Revenue growth | Total assets |
|---|---|---|---|---|---|
| Adaptive Biotechnologies ↗1478320 | $277.0m | $-59.5m | -21.5% | — | — |
| Neoleukin Therapeutics ↗1404644 | $0.0m | $-90.4m | — | — | — |
Explore full company accounts and filings.
Choose “View accounts” to inspect an available company preview.
Each pair uses the same year, currency and reporting basis. Cohort overlap is disclosed.
| Industry | Covered / eligible | Revenue total | Median revenue | Net profit / loss | Aggregate margin | Profitable share | Overlap |
|---|
Available-account cohorts are not estimates of whole industries. Overlapping entities can occur in more than one cohort; do not add cohort totals.
Filed annual accounts for exact designated national identifiers. Every aggregate and peer pair uses one fiscal year, source currency and reporting basis; periods, coverage and overlap are explicit; 2026 partials are excluded.
The same up to eight reporting entities remain open across years, filters and sorts. Other company figures are available in Radar.
Source currencies and accounting bases stay separate. Missing accounts are excluded rather than treated as zero. Exact reporting periods appear on company previews. Annual totals can change with coverage and do not measure growth of a fixed company cohort.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
19 companies hiring · $10.03B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Avalyn Pharma (AVLN), a clinical biotech pioneering inhaled treatments for rare respiratory disorders, priced its upsized IPO of 16.67 million shares at $18.00 – the top of its $16.00-to-$18.00 price range – and raised $300.06 million on Wednesday night, April 29, 2026.
Vistria, a middle market private investment firm with deep sector expertise across essential industries, announced the acquisition of Lumen, a technology-enabled Managing General Agent headquartered in Dallas, Texas.
Innovative eye treatment firm, Tenpoint Therapeutics, has raised $235M in a Series B round with support from Hillhouse Family Office
Qiagen announced that it would be acquiring single-cell omics firm Parse Biosciences.
Curi Bio – $10.0M
Synthesize Bio, a biotechnology company pioneering biological foundation models to simulate the results of gene expression experiments, today announced a $10 million seed round led by Madrona, with participation from Sahsen Ventures, Inner Loop Capital, Point Field Partners, and AI2 Incubator.
Private equity firm Pencarrow and iwi investor Ahuahu Group have invested an undisclosed amount in primary healthcare provider Tend Health.
Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has closed the sale of 3,358,208 shares of its common stock at a price to the public of $3.35 per share, ... Total gross proceeds from the offering, including the full exercise of the underwriters’ option, were approximately $86.3 million.
Spoke Acquisition Corporation (Spoke Sciences), Bethlehem, Northampton County
Gross proceeds from the offering were approximately $2.0 million.
Top 10 categories among 300 recorded events in the 24-month window.
10 companies with recorded IPO activity
IPO · NASDAQ5 reports
IPO · Nasdaq4 reports
IPO1 reports
IPO · NASDAQ2 reports
IPO · NASDAQ1 reports
IPO · NASDAQ3 reports
IPO · Nasdaq3 reports
Follow-on Offering · NASDAQ2 reports
18 tracked people moves
Appointment Director
Appointment Chief Executive Officer
Appointment Director
Appointment Executive Vice President, CFO
Appointment Executive Vice President and Chief Revenue Officer
Departure
Appointment Lead Independent Director
Appointment President and Chief Executive Officer
2 recorded customer wins
Customer: Isis Pharmaceuticals
Customer: abbott laboratories
6 companies with reported reductions
Scale not stated roles
9.0% roles
25 rolescost reduction
24 roles
70.0% roles
Scale not stated rolescash runway extension
5 recorded events
plan acceptedNYSE American
approved for tradingNYSE Regulation
symbol \'D\' temporarily allotted for 20 daysFINRA
approved to quote on OTCQBOTC Markets Group Inc.
7 tracked suits
securities laws violationsSecurities Fraud ·
securities laws violationsSecurities Fraud · Ongoing
Reported company results in the recorded window.
Median across 40 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| at&t→Lumen ↗ | Announced | 2026-03-10 | Not stated in snapshot |
| vistria→Lumen ↗ | Announced | 2026-02-25 | Not stated in snapshot |
| qiagen→Parse Biosciences ↗ | Announced | 2026-01-20 | Not stated in snapshot |
| alcon→Aurion Biotech ↗ | Announced | 2025-03-27 | Not stated in snapshot |
| Calypso Medical Technologies→Boston Scientific Corp | Announced | 2025-02-14 | $90.0M |
| Aquinox Pharmaceuticals Inc.→Neoleukin Therapeutics ↗ | Announced | 2025-02-14 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
376 postings in the preceding 12 months. The full 600-posting snapshot covers 19 employers.
5 tracked postings mention remote work.
286 postings specify a level.
Top skills across 600 tracked postings in the available jobs snapshot.
Median across 50 postings with pay data, expressed in USD.
| Company | Employees |
|---|---|
| Adaptive Biotechnologies ↗ | 609 |
| Sana Biotechnology ↗ | 328 |
| Truveta ↗ | 250 |
| CorneaGen ↗ | 205 |
| Umoja Biopharma ↗ | 168 |
| Impel NeuroPharma ↗ | 158 |
| Nautilus Biotechnology ↗ | 134 |
| Parse Biosciences ↗ | 107 |
231 founders and chief executives across 140 companies.
Co-Founder Lila Sciences, Flagship Pioneering, Tessera Therapeutics, Indigo. University of California San Diego MS 2005…
Founder Nautilus Biotechnology, ex-Isilon Systems, RealNetworks. University of Maryland 1996
Ex-Microsoft, Ramco Systems. National Institute of Technology Warangal MTech 1995, The Wharton School MBA 2010
Ex-Institute for Systems Biology, Southwest Research Institute. The University of Texas at Austin BS 1989, University of Washington PhD 2000
Life Science Washington, ex-Aortica, ex-American Heart Association, University of Pennsylvania - The Wharton School, 2002
Co-Founder Generation Bio, ex-Casebia Therapeutics, bluebird bio, Cellectis therapeutics. University of North Carolina School of Medicine MD 1993
Janssen Research and Development, ex-Astellas Pharma Global Development, Ocata Therapeutics. Columbia University AB 1984…
Tune Therapeutics, ex-Lyell Immunopharma, ex-Juno Therapeutics, university of pennsylvania, 2003
Orbimed Advisors, Silverback Therapeutics, Edgewise Therapeutics, Corvus Pharmaceuticals, Principia Biopharma, Cleave BioSciences…
CEO Black Kactus, ex-Sollers Partners, Founder HealthLink Global, SK Telecom. INSEAD MBA 1999, Luigi Bocconi Commercial University MPhil 2007
INSEAD MBA, Imperial College London MSc, PhD
Venture Partner - Samsara BioCapital. Princeton University Bachelor of Arts
56 profiles with education records.
12 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
2,382 articles in the measured 12-month window.
Life Sciences coverage tagged Seattle · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 994 |
| 2021Q3 | 901 |
| 2021Q4 | 833 |
| 2022Q1 | 981 |
| 2022Q2 | 829 |
| 2022Q3 | 885 |
| 2022Q4 | 809 |
| 2023Q1 | 798 |
| 2023Q2 | 1,004 |
| 2023Q3 | 700 |
| 2023Q4 | 837 |
| 2024Q1 | 856 |
| 2024Q2 | 900 |
| 2024Q3 | 818 |
| 2024Q4 | 808 |
| 2025Q1 | 5,032 |
| 2025Q2 | 526 |
| 2025Q3 | 598 |
| 2025Q4 | 700 |
| 2026Q1 | 603 |
Article volume measures coverage, not market sales.
458 recorded company events across 67 companies; percentages use that event total.
Life Sciences coverage tagged Seattle · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
United States comparison coverage
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| vaccine candidates | 3,157 | 898 | 252% |
| vaccine trials | 2,962 | 904 | 228% |
| vaccination campaigns | 2,752 | 555 | 396% |
| vaccine immunogenicity | 2,473 | 668 | 270% |
| mass vaccination sites | 2,021 | 272 | 643% |
| vaccination coverage | 1,516 | 202 | 650% |
| vaccine effectiveness study | 1,400 | 251 | 458% |
| angel investors | 1,344 | 590 | 128% |
| covid-19 vaccine development | 1,335 | 238 | 461% |
| pandemic vaccine stockpiling | 1,294 | 242 | 435% |
| investigational new vaccine | 451 | 1,069 | -58% |
| cell-based therapies | 619 | 1,059 | -42% |
| viral vector vaccines | 684 | 1,048 | -35% |
| cancer biomarkers | 670 | 1,040 | -36% |
| diagnostic biotechnology | 570 | 948 | -40% |
United States comparison coverage
core inflation rate, inflation outlook, inflation breakdown
52.8% critical · 34.6% positiveangel investors, vaccine candidates, vaccine trials
49.1% critical · 55.2% positivegdp acceleration, gdp growth rate, economic output growth
49.7% critical · 39.6% positiveLife Sciences coverage tagged Seattle. Topic labels describe recorded classifications and can include broad context.
6,260 papers in the recorded india scope.
Tone counts: 5,526 positive · 456 neutral · 278 negative.
Landmark: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term prob
Landmark: Genomic responses in mouse models poorly mimic human inflammatory diseases
Landmark: U1 snRNP regulates cancer cell migration and invasion in vitro
Common problems researchers identify · 0118.4% of this theme group
Researchers highlight difficulties in scaling synthetic biology, nanotech, and enzyme applications for industrial biotech processes.
Biochemical engineering (18) · Synthetic biology (12) · Biomanufacturing (8) · Nanotechnology (9)
Microbial Enzymes: Tools for Biotechnological Processes
Medical biofilms
| Year | Share index |
|---|---|
| 2022 | 67.9 |
| 2023 | 70.3 |
| 2024 | 84.4 |
| 2025 | 67.1 |
Common problems researchers identify · 0215.7% of this theme group
Papers flag rising public health threats from mycotoxins, pathogens, and unsafe produce handling.
Public health (15) · Mycotoxin (8) · Disease (12) · Contamination (8)
The growing burden of foodborne outbreaks due to contaminated fresh produce: risks and opportunities
A review of Listeria monocytogenes: An update on outbreaks, virulence, dose-response, ecology, and risk assessments
| Year | Share index |
|---|---|
| 2022 | 301.0 |
| 2023 | 265.8 |
| 2024 | 276.2 |
| 2025 | 304.0 |
Common problems researchers identify · 0315.5% of this theme group
Studies point to unresolved issues in mutation detection, DNA methylation profiling, and metabolic imaging for oncology.
Mutation (7) · Cancer (9) · DNA methylation (5) · Gene (8)
Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research
Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine
| Year | Share index |
|---|---|
| 2022 | 974.1 |
| 2023 | 1199.2 |
| 2024 | 866.8 |
| 2025 | 797.1 |
Common problems researchers identify · 0415.2% of this theme group
Researchers discuss obstacles in engineering crops for drought, salinity, and other non‑biotic stresses.
Agriculture (33) · Abiotic stress (10) · Abiotic component (12) · Biotechnology (20)
Genetic Engineering for Modern Agriculture: Challenges and Perspectives
Phytohormones and their metabolic engineering for abiotic stress tolerance in crop plants
| Year | Share index |
|---|---|
| 2022 | 1472.5 |
| 2023 | 1503.8 |
| 2024 | 1656.9 |
| 2025 | 1839.0 |
Common problems researchers identify · 0514.7% of this theme group
Works identify hurdles in biofortification, micronutrient production, and fermentative food technologies.
Micronutrient (9) · Production (13) · Nutrient (10) · Food science (7)
Improving nutrition through biofortification: A review of evidence from HarvestPlus, 2003 through 2016
Food fermentations: Microorganisms with technological beneficial use
| Year | Share index |
|---|---|
| 2022 | 120.6 |
| 2023 | 117.1 |
| 2024 | 113.1 |
| 2025 | 122.2 |
Common problems researchers identify · 0611.1% of this theme group
Authors emphasize the growing challenge of drug‑resistant bacteria and limited therapeutic options.
Antibiotic resistance (49) · Antimicrobial (31) · Antibiotics (22) · Drug resistance (8)
An overview of the antimicrobial resistance mechanisms of bacteria
The global threat of antimicrobial resistance: science for intervention
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Common problems researchers identify · 079.5% of this theme group
Papers note rising resistance in mosquitoes and pests, complicating integrated management strategies.
Resistance (14) · Insecticide resistance (5) · Vector (5) · Integrated pest management (5)
Insecticide Resistance in Mosquitoes: Impact, Mechanisms, and Research Directions
Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens
| Year | Share index |
|---|---|
| 2022 | 3.4 |
| 2023 | 3.1 |
| 2024 | 4.4 |
| 2025 | 4.3 |
Cautions · 0124.6% of this theme group
Researchers urge caution interpreting instability data and the impact of repair mechanisms on disease risk.
DNA repair (7) · DNA polymerase (6) · DNA damage (7) · Mutation (9)
Examining the link between chromosomal instability and aneuploidy in human cells
Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations
| Year | Share index |
|---|---|
| 2022 | 101.2 |
| 2023 | 139.0 |
| 2024 | 91.9 |
| 2025 | 79.2 |
Cautions · 0218.1% of this theme group
Studies caution about off‑target effects of antibodies and cellular responses in therapeutic contexts.
Antibody (9) · In vivo (8) · Peripheral blood mononuclear cell (4) · Immune system (5)
Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs
T cell responses towards PINK1 and ⍺-synuclein are elevated in prodromal Parkinson's disease - Fluorospot data
| Year | Share index |
|---|---|
| 2022 | 543.7 |
| 2023 | 602.0 |
| 2024 | 448.8 |
| 2025 | 441.1 |
Cautions · 0314.4% of this theme group
Works warn of potential hazards from novel ingredients, nanomaterials, and sugar‑related health impacts.
Food safety (6) · Raw material (4) · Health benefits (4) · Sugar (3)
Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters
Soybean susceptibility to manufactured nanomaterials with evidence for food quality and soil fertility interruption
| Year | Share index |
|---|---|
| 2022 | 122.8 |
| 2023 | 120.4 |
| 2024 | 118.6 |
| 2025 | 154.1 |
Cautions · 0411.6% of this theme group
Authors highlight uncertainties in feed additives, mineral supplementation, and their effects on animal health and emissions.
Dairy cattle (6) · Production (6) · Nutrient (6) · Beef cattle (5)
Impact of tannin-based additives on animal performance and enteric methane emissions in dairy and beef cattle: A meta-analysis
The effects of injectable trace mineral solutions on beef cattle performance and health during preconditioning and feedlot receiving: a syst
| Year | Share index |
|---|---|
| 2022 | 126.8 |
| 2023 | 122.4 |
| 2024 | 118.5 |
| 2025 | 129.2 |
Cautions · 0510.8% of this theme group
Papers discuss challenges in applying genomic tools for trait prediction and selection accuracy.
Gene (10) · Genomic selection (5) · Selection (6) · Trait (4)
Genomic Selection for Crop Improvement
Genomic selection in plant breeding: from theory to practice
| Year | Share index |
|---|---|
| 2022 | 2367.9 |
| 2023 | 2351.5 |
| 2024 | 2081.1 |
| 2025 | 1566.0 |
Cautions · 0610.5% of this theme group
Research points to possible drawbacks of biological controls and resistance emergence in pest strategies.
PEST analysis (9) · Agriculture (7) · Pest control (3) · Integrated pest management (3)
The use of fungal entomopathogens as endophytes in biological control: a review
Insecticide Control of Vector-Borne Diseases: When Is Insecticide Resistance a Problem?
| Year | Share index |
|---|---|
| 2022 | 1443.5 |
| 2023 | 1484.3 |
| 2024 | 1642.9 |
| 2025 | 1827.1 |
Cautions · 079.9% of this theme group
Studies caution about cross‑species resistance propagation from veterinary antibiotic practices.
Antibiotic resistance (12) · Antibiotics (9) · Antimicrobial (6) · Bacteria (5)
Multidrug evolutionary strategies to reverse antibiotic resistance
Impact of Antibiotic Use in Adult Dairy Cows on Antimicrobial Resistance of Veterinary and Human Pathogens: A Comprehensive Review
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Opportunities · 0119.6% of this theme group
Opportunities focus on microbial fermentation to enhance health, nutrition, and animal performance.
Antimicrobial (64) · Fermentation (55) · Bacteria (52) · Antibiotic resistance (37)
Probiotics, their health benefits and applications for developing healthier foods: a review
Postbiotics: Multifunctional Microbial Products Transforming Animal Health and Performance
| Year | Share index |
|---|---|
| 2022 | 2406.7 |
| 2023 | 2240.7 |
| 2024 | 2316.1 |
| 2025 | 1955.8 |
Opportunities · 0219.3% of this theme group
Research explores knockdown, apoptosis control, and pathway tuning for disease treatment.
Apoptosis (37) · Downregulation and upregulation (57) · Gene knockdown (46) · Mutant (48)
PCBP1 binding to single-stranded poly-cytosine motifs enhances cGAS sensing and impairs breast cancer development
Modulation of ossification and inflammatory pathways during dexamethasone-induced <i>in vitro</i> osteogenesis
| Year | Share index |
|---|---|
| 2022 | 364.0 |
| 2023 | 394.7 |
| 2024 | 257.4 |
| 2025 | 261.8 |
Opportunities · 0313.2% of this theme group
Papers highlight advances in T‑cell engineering, antigen presentation, and tumor‑immune interactions.
Cell culture (77) · T cell (54) · Antigen (49) · Cell (62)
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Tumor-Derived Microvesicles Promote Regulatory T Cell Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8+ T Lymphocytes
| Year | Share index |
|---|---|
| 2022 | 289.3 |
| 2023 | 336.1 |
| 2024 | 224.8 |
| 2025 | 204.1 |
Opportunities · 0412.8% of this theme group
Studies present novel approaches to modify methylation and repair pathways for therapeutic benefit.
DNA repair (65) · DNA damage (68) · DNA methylation (58) · DNA replication (34)
Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders
MacroH2A-Mediated Gene Repression through Nucleosome Compaction and Remodeling Inhibition
| Year | Share index |
|---|---|
| 2022 | 224.2 |
| 2023 | 281.6 |
| 2024 | 196.5 |
| 2025 | 158.4 |
Opportunities · 0512.2% of this theme group
Works showcase fluorescent and MRI nanoparticle probes for real‑time tracking of biological processes.
In vivo (142) · Fluorescence (41) · Molecular imaging (28) · Nanotechnology (33)
Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases
Recognition, Neutralization, and Clearance of Target Peptides in the Bloodstream of Living Mice by Molecularly Imprinted Polymer Nanoparticl
| Year | Share index |
|---|---|
| 2022 | 480.4 |
| 2023 | 520.5 |
| 2024 | 397.5 |
| 2025 | 406.8 |
Opportunities · 0611.7% of this theme group
Research leverages sequencing and germplasm analysis to accelerate breeding of resilient varieties.
Germplasm (37) · Selection (42) · Genetic diversity (28) · Trait (28)
Genotyping‐by‐Sequencing for Plant Breeding and Genetics
Harvesting the Promising Fruits of Genomics: Applying Genome Sequencing Technologies to Crop Breeding
| Year | Share index |
|---|---|
| 2022 | 56.0 |
| 2023 | 51.4 |
| 2024 | 46.1 |
| 2025 | 53.1 |
Opportunities · 0711.3% of this theme group
Papers investigate mRNA methylation, microRNA dynamics, and transcriptional control for disease and development.
Messenger RNA (103) · microRNA (61) · Transcription (65) · RNA polymerase II (34)
m <sup>6</sup> A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation
Microrna-Dependent Regulation of Dna Methyltransferase-1 and Tumor Suppressor Gene Expression by Interleukin-6 in Human Malignant Cholangioc
| Year | Share index |
|---|---|
| 2022 | 229.2 |
| 2023 | 195.8 |
| 2024 | 157.3 |
| 2025 | 136.5 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Breakthrough | 32.6% | 26.6% |
| Promising | 31.0% | 36.9% |
| Descriptive | 17.5% | 17.8% |
| Problem-identifying | 9.1% | 9.5% |
| Cautionary | 5.8% | 4.6% |
| Comparative | 2.8% | 3.8% |
| Critical | 1.3% | 0.9% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities | 18 | 0.3% | 2 (11.1%) | 0.21% |
| Hardware, e-waste & supply chainFate and Transport of Antibiotic Residues and Antibiotic Resistance Genes following Land Application of Manure Waste | 4 | 0.07% | 1 (25.0%) | 0.15% |
| Bias & fairnessNot All Allies Are Welcome: Partner Discrimination in Legume–Rhizobium Symbiosis | 3 | 0.05% | 1 (33.3%) | 0.03% |
| Safety & misusePublic perceptions and information sources on genetically modified organisms in Kenya | 1 | 0.02% | 1 (100.0%) | 0.01% |
| Energy & datacenter footprint | 0 | 0.0% | 0 (%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Labour & data work | 0 | 0.0% | 0 (%) | 0.0% |
| Concentration of compute power | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: United States. This may be broader than the company geography.
Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 4 September 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗